Drug: Pembrolizumab (Keytruda, Merck)
Status: Approved in combination with pemetrexed (Alimta, Eli Lilly) and carboplatin (Paraplatin, Bristol-Myers Squibb) (pem/carbo) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression
Significant Information:
- Based on the KEYNOTE-021 trial, which evaluated the combination treatment in 123 previously untreated patients with metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor